Home Liver DiseasesLiver Cancer Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma

Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma

Credits to the Source Link Daniel
Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma
  • 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 2.

    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 3.

    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl J Med. 2008;359:378–90.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 4.

    Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma. 2017;4:131–8.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 5.

    Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharm Sin. 2017;38:614–22.

    CAS 
    Article 

    Google Scholar
     

  • 6.

    Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 7.

    Taniguchi K, Karin MNF-kappaB. inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309–24.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 8.

    Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62:534–45.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 9.

    Liang L, Wu J, Luo J, Wang L, Chen ZX, Han CL, et al. Oxymatrine reverses 5-fluorouracil resistance by inhibition of colon cancer cell epithelial-mesenchymal transition and NF-kappaB signaling in vitro. Oncol Lett. 2020;19:519–26.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 10.

    Wang Y, Jiang F, Jiao K, Ju L, Liu Q, Li Y, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-kappaB pathway and CSC like properties. Exp Cell Res. 2020;386:111739.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 11.

    Neelgundmath M, Dinesh KR, Mohan CD, Li F, Dai X, Siveen KS, et al. Novel synthetic coumarins that targets NF-kappaB in Hepatocellular carcinoma. Bioorg Med Chem Lett. 2015;25:893–7.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 12.

    Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W, et al. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3eta/NF-kappaB feedback loop. J Exp Clin Cancer Res. 2018;37:321.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 13.

    Jing H, Shen G, Wang G, Zhang F, Li Y, Luo F, et al. MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFkappaB pathways. J Surg Res. 2012;176:63–73.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 14.

    Ren J, Chen GG, Liu Y, Su X, Hu B, Leung BC, et al. Cytochrome P450 1A2 metabolizes 17beta-Estradiol to suppress hepatocellular carcinoma. PLoS One. 2016;11:e0153863.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 15.

    Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kappaB. Cancer Cell. 2013;24:423–37.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 16.

    Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharm Toxicol. 2007;100:23–30.

    CAS 
    Article 

    Google Scholar
     

  • 17.

    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 2016;371:171–81.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 18.

    Galmiche A, Chauffert B, Barbare JC. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014;346:159–62.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 19.

    Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010;1805:167–80.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 20.

    Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-kappaB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget. 2016;7:85450–63.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 21.

    Li J, Zhou Y, Liu Y, Dai B, Zhang YH, Zhang PF, et al. Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biol Ther. 2018;19:1057–64.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 22.

    Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3beta and NF-kappaB to suppress tumor cell growth. Oncogene. 2012;31:4848–58.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 23.

    Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, et al. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278:145–55.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 24.

    Tatebe S. Cardiologists and the management of obstetric venous thromboembolism. Circ J. 2015;79:1215–7.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 25.

    Chen H, Shen ZY, Xu W, Fan TY, Li J, Lu YF, et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol. 2014;20:8681–90.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 26.

    Liu ZZ, Yan LN, Dong CN, Ma N, Yuan MN, Zhou J, et al. Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: an integrated analysis of gene expression profiles. Saudi J Gastroenterol. 2019;25:167–75.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 27.

    Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1991;36:394–404.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 28.

    Martin de Argila C. Safety of potent gastric acid inhibition. Drugs. 2005;65:97–104.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 29.

    Chen CH, Lee CZ, Lin YC, Kao LT, Lin HC. Negative association of proton pump inhibitors with subsequent development of breast cancer: a nationwide population-based study. J Clin Pharm. 2019;59:350–5.

    CAS 
    Article 

    Google Scholar
     

  • 30.

    Papagerakis S, Bellile E, Peterson LA, Pliakas M, Balaskas K, Selman S, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res. 2014;7:1258–69.

    CAS 
    Article 

    Google Scholar
     

  • 31.

    Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–13.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 32.

    Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharm Res. 2019;150:104511.

    CAS 
    Article 

    Google Scholar
     

  • 33.

    Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69–78.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 34.

    MacNab GM, Alexander JJ, Lecatsas G, Bey EM, Urbanowicz JM. Hepatitis B surface antigen produced by a human hepatoma cell line. Br J Cancer. 1976;34:509–15.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 35.

    Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001–14.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 36.

    Sainz B Jr., TenCate V, Uprichard SL. Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection. Virol J. 2009;6:103.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 37.

    Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, et al. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol. 1996;70:641–6.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 38.

    Su F, Schneider RJ. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol. 1996;70:4558–66.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 39.

    Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C, et al. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol. 1999;19:6345–54.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 40.

    Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology. 2010;138:2509-18–2518 e2501.


    Google Scholar
     

  • 41.

    Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J Biol Chem. 2003;278:40778–87.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 42.

    Yamada T, Abei M, Danjoh I, Shirota R, Yamashita T, Hyodo I, et al. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. BMC Cancer. 2015;15:260.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 43.

    Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, et al. Inconsistency in large pharmacogenomic studies. Nature. 2013;504:389–93.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 44.

    Shen ZT, Chen Y, Huang GC, Zhu XX, Wang R, Chen LB. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-kappaB signaling pathway. BMC Cancer. 2019;19:1075.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 45.

    Xie C, Zhang LZ, Chen ZL, Zhong WJ, Fang JH, Zhu Y et al. A hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in NF kappa B signaling and chemoresistance. Hepatology. 2020;71:1660–77.

  • 46.

    Wang N, Li MY, Liu Y, Yu J, Ren J, Zheng Z, et al. ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway. Cancer Lett. 2020;472:70–80.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: